



Eurostars Grant won by TBD / Studio Mango / VEDS consortium

Renens, 03.08.2022. Today, the TBD / Studio Mango / VEDS consortium proudly announced that they won a prestigious Eurostars grant. It is the largest international funding program for SMEs wishing to collaborate on R&D projects that create innovative products, processes, or services for commercialization.

The funding will support the joint product development while fostering international collaboration with several countries. The partners are based in Estonia (TBD Biodiscovery) and the Netherlands (Studio Mango and VEDS).

About Lumendo: Incorporated in Switzerland in 2018 as Spin-off of the two Swiss Federal Institutes of Technology – École Polytechnique Fédéral de Lausanne (EPFL) and Eidgenössische Technische Hochschule Zürich (ETH) – Lumendo is a well-recognized upcoming disruptor in the field of endodontics. Focusing on product excellence and a strong innovation stream, the goal of Lumendo is to develop easy-to-apply, reliable, and novel products to treat unsolved medical challenges.

About TBD Biodiscovery: A Contract Development and Manufacturing (CDMO) with 16 years of experience, located in Tartu, Estonia. TBD-Biodiscovery specialises in Active Pharmaceutical Ingredients (API), advanced intermediates, and the development and production of fine chemicals. Combining GMP-compliant production with strong R&D and extensive experience in the validation process, TBD-Biodiscovery is focused on contributing its knowledge and technical skills to modern healthcare.

About Studio Mango: Studio Mango is a full-service industrial design & mechanical engineering company which develops innovative products for a wide diversity of clients. Founded in 2005 at the technical university of Delft in the Netherlands. Our aim is to create beautiful, distinctive & meaningful products with an eye for sustainability and affordability. Many of the projects executed by the company are medical device developments for which Studio Mango is specifically ISO9001 certified. For Lumendo assistance will be given to develop the best possible root canal treatment system which works better both for patient and dentist, saves time thus money and on top all of that looks great as well.

About VEDS: VEDS Group is a one stop shop engineering company, situated at the High Tech Campus in Eindhoven (NL), which develops hardware, embedded software, frontend and backend software for a broad range of clients. Also the production of (prototype) PCBA's is inhouse in Eindhoven to provide a quick and reliable product.

VEDS Group is ISO9001:2015 and ISO13485:2016 certified. This means that a lot of medical clients find their way to the VEDS Group. We support Lumendo with the development of the root canal treatment system and the hardware and software part of this upcoming product. Later on, the prototype production of the hardware can be done by VEDS Group as well.



About the technology: Root canal treatments are one of the most difficult treatments for dentists, traditionally with very low success rates between 46-91%¹. With more than 60 million annual treatments worldwide, these failures lead to a substantial increase in health care costs.

One major cause of the treatment failure can be traced back to the use of endodontic files that may result in root or instrument fractures. Another issue is the inefficient identification and disinfection of the often very complex root canal anatomy. Finally, a major problem is the obturation of these geometrically complex morphologies with viscous or rubber-like materials that are difficult to be distributed adequately in narrow canals, leading to voids that can be reinfected.

The goal of Lumendo's technology platform is to offer better treatment options to dentists and their patients. The company's first products are planned to be launched in 2024.

Disclaimer: Lumendo's devices are in development and not approved for clinical use under any jurisdiction.

For further information contact:

Lumendo AG

Chemin du Closel 5

CH-1020 Renens

Switzerland

info@lumendo.ch

www.lumendo.ch



¹ S. Friedman, "Prognosis of initial endodontic therapy," Endod. Top., vol. 2, no. 1, pp. 59–88, Jul. 2002.